Cancer News and Research

RSS
Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
New study pinpoints key source of T cell "exhaustion"

New study pinpoints key source of T cell "exhaustion"

Inaugural college and career program for oncology, hematology patients helps 'unlock' their future

Inaugural college and career program for oncology, hematology patients helps 'unlock' their future

Keeping lymph nodes in the body can boost the efficacy of cancer immunotherapy

Keeping lymph nodes in the body can boost the efficacy of cancer immunotherapy

DNA drugs help restore the normal processing of protein-encoding RNA

DNA drugs help restore the normal processing of protein-encoding RNA

Uncovering the role of the third intracellular loop in the GPCR’s signaling mechanism

Uncovering the role of the third intracellular loop in the GPCR’s signaling mechanism

Macrophages likely to be a potential target for ER+ breast cancer

Macrophages likely to be a potential target for ER+ breast cancer

Perspectives on nucleolar DNA damage response in the fight against cancer

Perspectives on nucleolar DNA damage response in the fight against cancer

Study discovers the ability of certain blood immune cells to proliferate

Study discovers the ability of certain blood immune cells to proliferate

Researchers uncover the role of third intracellular loop in GPCR's signaling mechanism

Researchers uncover the role of third intracellular loop in GPCR's signaling mechanism

Immune landscape in invasive ER+ breast cancers reveals a macrophage-driven microenvironment

Immune landscape in invasive ER+ breast cancers reveals a macrophage-driven microenvironment

New combination therapy regimen may reduce prostate cancer progression or death by 37%

New combination therapy regimen may reduce prostate cancer progression or death by 37%

Cancer cells use new DNA repair mechanism to recover from next-generation cancer radiation therapy

Cancer cells use new DNA repair mechanism to recover from next-generation cancer radiation therapy

Delaying paralysis in ALS by using designer DNA drug

Delaying paralysis in ALS by using designer DNA drug

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

Using a programmable control switch to deliver therapeutic RNA molecules to target cells

Using a programmable control switch to deliver therapeutic RNA molecules to target cells

Potential approach to improve solid tumor T cell therapy

Potential approach to improve solid tumor T cell therapy

The impact of genome doubling on the development of cancer

The impact of genome doubling on the development of cancer

Highlighting a potential sex‐specific precision immunotherapy strategy

Highlighting a potential sex‐specific precision immunotherapy strategy

Using PET and electron microscopy to generate 3D maps of mitochondrial networks in lung tumors

Using PET and electron microscopy to generate 3D maps of mitochondrial networks in lung tumors

High doses of sucralose limit T cell proliferation and differentiation

High doses of sucralose limit T cell proliferation and differentiation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.